← Back to Search

Vessel Interruption Order for Lung Cancer (CTC-01 Trial)

N/A

Waitlist Available

Led By Massimo Conti, MD

Research Sponsored by Laval University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Clinical stage tumor-1 to 3, clinical stage node-0, clinical stage metastasis-0 (except clinical stage tumor-3 for chest wall, pericardium or phrenic nerve invasion)

NSCLC with preoperative pathological evidence

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 96 hours after surgery

Awards & highlights

CTC-01 Trial Summary

This trial will help determine if the order in which a surgeon interrupts the vessels leading to a tumor affects the density of cancer cells in the area.

Who is the study for?

This trial is for adults with non-small cell lung cancer (NSCLC) who have a certain type of tumor visible on a CT scan and are in the early stages of the disease. They must be candidates for minimally invasive lung surgery but haven't had thoracic surgery on the same side before, nor can they have received recent cancer treatment or have another active cancer.Check my eligibility

What is being tested?

The study is testing whether interrupting blood flow through veins before other surgical steps, or arteries before veins, affects circulating tumor cells during lung cancer surgery. The goal is to see if changing this sequence impacts how many tumor cells spread from the lungs into the blood.See study design

What are the potential side effects?

Since this trial focuses on surgical technique rather than medication, typical drug-related side effects aren't expected. However, risks may include those associated with any surgical procedure such as bleeding, infection, and complications related to anesthesia.

CTC-01 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is in an early stage and has not spread to lymph nodes or other parts of the body.

Select...

My lung cancer was confirmed by a biopsy before surgery.

Select...

I had a minimally invasive lung surgery.

CTC-01 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 96 hours after surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 96 hours after surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 96 hours after surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in CTC clusters density

Changes in CTC density

Secondary outcome measures

Disease free survival

Overall survival

CTC-01 Trial Design

2Treatment groups

Active Control

Group I: Arteries before veinActive Control1 Intervention

Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.

Group II: Vein firstActive Control1 Intervention

Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor

417 Previous Clinical Trials

172,242 Total Patients Enrolled

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER

36 Previous Clinical Trials

9,712 Total Patients Enrolled

Massimo Conti, MDPrincipal InvestigatorCentre de Recherche IUCPQ - Laval University

Media Library

Arteries interruption before vein interruption Clinical Trial Eligibility Overview. Trial Name: NCT03645252 — N/A

Lung Cancer Research Study Groups: Arteries before vein, Vein first

Lung Cancer Clinical Trial 2023: Arteries interruption before vein interruption Highlights & Side Effects. Trial Name: NCT03645252 — N/A

Arteries interruption before vein interruption 2023 Treatment Timeline for Medical Study. Trial Name: NCT03645252 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research study recruiting participants at the moment?

"As indicated on clinicaltrials.gov, the current iteration of this medical experiment is not enlisting participants; it was first published on August 31st 2018 and updated most recently on the 22nd of that same month. Fortunately, there are 1898 other trials actively looking for volunteers at present."

Answered by AI

Recent research and studies

Journal of Thoracic OncologyJournal

Circulating Tumor Cells Detected in the Tumor-draining Pulmonary Vein Are Associated with Disease Recurrence After Surgical Resection of NSCLC

Crosbie, Phil A.J., Rajesh Shah, Piotr Krysiak, Cong Zhou, Karen Morris, Jonathan Tugwood, Richard Booton, Fiona Blackhall, and Caroline Dive. 2016. “Circulating Tumor Cells Detected in the Tumor-draining Pulmonary Vein Are Associated with Disease Recurrence After Surgical Resection of NSCLC”. Journal of Thoracic Oncology. Elsevier BV. doi:10.1016/j.jtho.2016.06.017.

Interactive CardioVascular and Thoracic SurgeryJournal

Significant Increase in Circulating Tumour Cells in Pulmonary Venous Blood During Surgical Manipulation in Patients with Primary Lung Cancer

Hashimoto, Masaki, Fumihiro Tanaka, Kazue Yoneda, Teruhisa Takuwa, Seiji Matsumoto, Yoshitomo Okumura, Nobuyuki Kondo, et al.. 2014. “Significant Increase in Circulating Tumour Cells in Pulmonary Venous Blood During Surgical Manipulation in Patients with Primary Lung Cancer”. Interactive Cardiovascular and Thoracic Surgery. Oxford University Press (OUP). doi:10.1093/icvts/ivu048.

clinicaltrials.govStudy

Sequence of Vessel Interruption and Circulating Tumor Cells in Surgical Lung Cancer

Massimo Conti 2018. "Sequence of Vessel Interruption and Circulating Tumor Cells in Surgical Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03645252.